Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.

Thaweesak Chieochansin¹, Kornkan Choomee², Napat Angkathunyakul³, Ananya Pongpaibul³, Prawat Kositamongkol⁴, Prawej Mahawithitwong⁴, Chutwichai Tovikkai⁴, Wethit Dumronggittigule⁴, Pholasith Sangserestid⁴, Charnwit Assawasirisin⁴, Yongyut Sirivatanauksorn⁴, Mutita Junking², Pa-Thai Yenchitsomanus⁵

¹Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Hematología computacional y genómica (GrHeCo-Xen), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Electronic address: thaweesak.chieochansin@gmail.com.

²Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

³Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.

⁴Hepatopancreatobiliary and Transplant Surgery Unit, Division of General Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.

⁵Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Electronic address: pathai.yen@mahidol.ac.th.

PubMed DOI

Abstract

hepatocellular carcinoma (HCC) is the most common primary liver cancer and remains difficult to treat in advanced stages because of tumor heterogeneity and an immunosuppressive microenvironment. Chimeric antigen receptor (CAR) T-cell therapy is an emerging strategy for solid tumors, but optimal CAR architecture for HCC remains under investigation. This study compared second-generation (anti-GPC3 C…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.